Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Review, H2 2016', provides in depth analysis on Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted pipeline therapeutics. The report provides comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects - The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Overview 6 Therapeutics Development 7 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Products under Development by Stage of Development 7 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Products under Development by Therapy Area 8 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Products under Development by Indication 9 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Products under Development by Companies 12 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development 20 Paradigm Biopharmaceuticals Limited 20 Pfizer Inc. 21 Takeda Pharmaceutical Company Limited 22 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles 23 Pelladerm - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 pentosan polysulfate sodium - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 PF-152 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Projects 30 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products 31 Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Featured News & Press Releases 32 Sep 16, 2016: Preclinical study underpins efficacy of Paradigms Rhinosul for hay fever treatment 32 Sep 07, 2016: Paradigm's PPS as a potential breakthrough in t he treatment of viral arthritis and joint pain 32 Aug 19, 2016: Market update Paradigm's PPS nasal spray to treat Allergic Rhinitis (Hay Fever) 34 Mar 02, 2016: Paradigm initiates second clinical trial site to investigate ZILOSUL as a treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury 35 Feb 25, 2016: First participant in Paradigm's clinical trial starts ZILOSUL treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury 36 Feb 23, 2016: Paradigm starts clinical trial to investigate ZILOSUL as a treatment for bone bruising following Anterior Cruciate Ligament (ACL) injury 36 Dec 03, 2015: Elite athlete from a major sporting code treated with Paradigm's ZILOSUL under the Therapeutic Goods Administration's Special Access Scheme 37 Nov 23, 2015: Paradigm's ZILOSUL approved for clinical trial 38 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 40 Disclaimer 41
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Assessment by Monotherapy/Combination Products, H2 2016 14 Number of Products by Stage and Mechanism of Action, H2 2016 15 Number of Products by Stage and Route of Administration, H2 2016 17 Number of Products by Stage and Molecule Type, H2 2016 19 Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016 20 Pipeline by Pfizer Inc., H2 2016 21 Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 22 Dormant Projects, H2 2016 30 Discontinued Products, H2 2016 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
